PLRX Company Profile and Key Details

Q: Who are the executives of PLRX?

Mr. Mike OuimetteGen. Counsel & Corporation Sec.Mr. Hal Chapman M.D.Scientific Founder & Member of Scientific Advisory BoardDr. Rik DerynckScientific Founder & Member of Scientific Advisory BoardMr. Johannes P. HullChief Bus. OfficerMr. Bill DeGrado Ph.D.Scientific Founder & Member of Scientific Advisory BoardDr. Keith Lamont Cummings M.B.A., M.D.Chief Financial OfficerDr. Éric Lefebvre M.D.Chief Medical OfficerMr. Craig D. MuirInterim Chief Technology OfficerMr. Dean Sheppard M.D.Scientific Founder & Member of Scientific Advisory BoardMr. Mike Ouimette J.D.Gen. Counsel & Corporation Sec.Dr. Bernard Coulie M.B.A., M.D., MBA, Ph.D.Pres, Chief Executive Officer & Director

NASDAQ : PLRX

Pliant Therapeutics

$1.16

At Close 4:00 PM

58.8

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Pliant Therapeutics, Inc. (PLRX) stock remained unchanged at $1.16 a share on NASDAQ. The stock opened at $1.17, fluctuating between $1.14 to $1.18 during the session.

Stock Snapshot

1.16

Prev. Close

71.83M

Market Cap

1.14

Day Low

-0.63

P/E Ratio

-1.85

EPS (TTM)

-1.96

Cash Flow per Share

1.17

Open

61.92M

Number of Shares

1.1777

Day High

83.87%

Free Float in %

7.91

Book Value

227.78K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 22, 2026	1.17	1.18	1.14	1.16	227.79K
Jun 18, 2026	1.20	1.20	1.14	1.16	472.4K
Jun 17, 2026	1.19	1.20	1.17	1.18	303.29K
Jun 16, 2026	1.14	1.19	1.14	1.19	513.36K
Jun 15, 2026	1.16	1.16	1.12	1.14	375.2K
Jun 12, 2026	1.15	1.17	1.13	1.13	207.21K
Jun 11, 2026	1.19	1.19	1.13	1.14	491.6K
Jun 10, 2026	1.19	1.21	1.15	1.16	345.46K
Jun 09, 2026	1.16	1.20	1.13	1.19	279.84K
Jun 08, 2026	1.14	1.16	1.13	1.15	169.38K
Jun 05, 2026	1.16	1.18	1.13	1.15	409.1K
Jun 04, 2026	1.17	1.21	1.16	1.17	321.08K
Jun 03, 2026	1.18	1.20	1.14	1.18	1.59M
Jun 01, 2026	1.26	1.26	1.20	1.20	756.12K
May 29, 2026	1.25	1.27	1.24	1.26	314.92K
May 28, 2026	1.22	1.26	1.22	1.25	210.35K
May 27, 2026	1.25	1.26	1.24	1.24	216.69K
May 26, 2026	1.22	1.26	1.21	1.24	694.11K
May 22, 2026	1.24	1.26	1.20	1.21	212.12K
May 21, 2026	1.21	1.25	1.19	1.23	269.72K

Contact Details

South San Francisco, CA 94080

United States

https://pliantrx.com 650 481 6770

About Company

Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.

Stock Peers

ARGX

26.03+2.97%

argenx SE$903.75 REGN

2.56+0.42%

Regeneron Pharmaceuticals, Inc.$612.50 UTHR

1.70998+0.32%

United Therapeutics Corporation$538.30 MDGL

7.13+1.41%

Madrigal Pharmaceuticals, Inc.$512.88 VRTX

15.16+3.36%

Vertex Pharmaceuticals Incorporated$466.79 KRYS

-4.63-1.33%

Krystal Biotech, Inc.$343.43 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

21.08+7.47%

Praxis Precision Medicines, Inc.$303.39 ALNY

8.32+2.99%

Alnylam Pharmaceuticals, Inc.$286.41 LGND

-12.71-4.62%

Ligand Pharmaceuticals Incorporated$262.17

Frequently Asked Questions

What is the current Pliant Therapeutics, Inc. (PLRX) stock price?

Pliant Therapeutics, Inc. (NASDAQ: PLRX) stock price is $1.16 in the last trading session. During the trading session, PLRX stock reached the peak price of $1.18 while $1.14 was the lowest point it dropped to. The percentage change in PLRX stock occurred in the recent session was 0% while the dollar amount for the price change in PLRX stock was $0.00.

PLRX's industry and sector of operation?

The NASDAQ listed PLRX is part of Biotechnology industry that operates in the broader Healthcare sector. Pliant Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PLRX?

Mr. Mike Ouimette
Gen. Counsel & Corporation Sec.
Mr. Hal Chapman M.D.
Scientific Founder & Member of Scientific Advisory Board
Dr. Rik Derynck
Scientific Founder & Member of Scientific Advisory Board
Mr. Johannes P. Hull
Chief Bus. Officer
Mr. Bill DeGrado Ph.D.
Scientific Founder & Member of Scientific Advisory Board
Dr. Keith Lamont Cummings M.B.A., M.D.
Chief Financial Officer
Dr. Éric Lefebvre M.D.
Chief Medical Officer
Mr. Craig D. Muir
Interim Chief Technology Officer
Mr. Dean Sheppard M.D.
Scientific Founder & Member of Scientific Advisory Board
Mr. Mike Ouimette J.D.
Gen. Counsel & Corporation Sec.
Dr. Bernard Coulie M.B.A., M.D., MBA, Ph.D.
Pres, Chief Executive Officer & Director

How PLRX did perform over past 52-week?

PLRX's closing price is 6.42% higher than its 52-week low of $1.09 where as its distance from 52-week high of $1.95 is -40.51%.

How many employees does PLRX have?

Number of PLRX employees currently stands at 171.

Link for PLRX official website?

Official Website of PLRX is: https://pliantrx.com

How do I contact PLRX?

PLRX could be contacted at phone 650 481 6770 and can also be accessed through its website. PLRX operates from 260 Littlefield Avenue, South San Francisco, CA 94080, United States.

How many shares of PLRX are traded daily?

PLRX stock volume for the day was 227.78K shares. The average number of PLRX shares traded daily for last 3 months was 489.97K.

What is the market cap of PLRX currently?

The market value of PLRX currently stands at $71.83M with its latest stock price at $1.16 and 61.92M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	171
Beta	1.21
Sales or Revenue	$1.58M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	171
Beta	1.21
Sales or Revenue	$1.58M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

PLRX Company Profile and Key Details

Pliant Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook